WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The company operates a chain of mid-sized multi-speciality hospitals
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated